イタリア - イタリア語 - Ministero della Salute

massimo zero srl -

欧州連合 - イタリア語 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - gefapixant - cough - preparati per la tosse e il freddo - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

serb sa - idrossicobalamina - avvelenamento - tutti gli altri prodotti terapeutici - trattamento dell'avvelenamento da cianuro noto o sospetto. cyanokit deve essere somministrato insieme adeguata decontaminazione e misure di sostegno.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - orlistat - obesità - preparazioni antiobesità, escl. prodotti dietetici - xenical è indicato in associazione ad una dieta moderatamente ipocalorica per il trattamento di pazienti obesi con un indice di massa corporea (bmi) maggiore o uguale a 30 kg/m2, o di pazienti in sovrappeso (bmi > 28 kg/m2) con fattori di rischio associati. il trattamento con orlistat deve essere interrotto dopo 12 settimane, se i pazienti sono stati in grado di perdere almeno il 5% del peso corporeo misurato all'inizio della terapia.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti per dermatiti, esclusi i corticosteroidi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - orlistat - obesità - preparazioni antiobesità, escl. prodotti dietetici - alli è indicato per la perdita di peso negli adulti in sovrappeso (indice di massa corporea, bmi, ≥ 28 kg / m2) e deve essere assunto in associazione con una dieta moderatamente ipocalorica e con pochi grassi.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - asma - farmaci per le malattie respiratorie ostruttive, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

イタリア - イタリア語 - Ministero della Salute

venturoli sementi - rame ossalato; - polvere - 4.0 g i valori indicati sono per 100 g di prodotto.

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - enalapril e lercanidipina - enalapril e lercanidipina

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - enalapril e lercanidipina - enalapril e lercanidipina